ELEMENTS OF A DATA MONITORING PLAN

Similar documents
FDA Sponsor and Investigator Responsibility Checklist

Implementing Good Clinical Practice at an Academic Research Institution

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Sponsor-Investigator Responsibilities In Clinical Trials

Compliance and Quality Monitoring: What, Why, When, and How

1 The Clinical Research Coordinator (CRC)... 1

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

Source Documents and Regulatory Binders October 6, 2016

Sponsor/Investigator Responsibilities

Regulatory Binder: Set-up and Maintenance

SELF-ASSESSMENT CHECKLIST

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH

Standard Operating Procedures (SOPs)

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

Regulatory Binder Guidance

Cancer Center Clinical Trials Office

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

Human Research Protection Program Policy

SOP#: Original Approval Date: 3/25/13

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor

Human Research Protection Program Policy

Good Clinical Practice

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1

Standard Operating Procedures Guidelines for Good Clinical Practice

Responsibilities of Investigators for Clinical Trials from Consent to Safety Reporting

HUMAN RESEARCH PROTECTION PROGRAM PLAN

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.

K E M R I STANDARD OPERATING PROCEDURE FOR ROUTINE AND FOR- CAUSE AUDITS

13.0 Quality Improvement in the HRPP Program

Regulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

ORC Sponsor-Investigator IDE Checklist

OCTC 2012 CRO Selection

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

FDA Inspections: FDA Inspections: An Overview Overview

GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018

Tier Assessment/Setting - Quick Guide to Competency Levels

1. POLICY STATEMENT: 2. BACKGROUND:

CONTACT INFORMATION. PHRC Office. Josephine O Driscoll-Davis. Michael Ducey

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol

TITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19

4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.

EVENT TYPE TIMING REQUIRED FORM

ORIGINATION DATE: 01/01/2011 FINAL APPROVAL DATE: April 30, This procedure applies to all clinical trials conducted at any IASIS Facility.

Volunteering for Clinical Trials

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File

RESEARCH AUDIT Standard Operating Procedure

Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators

Clinical Trials Management for Molecular Diagnostics. April 2016

Recommendations for Strengthening the Investigator Site Community

ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.

Office for Human Subject Protection. University of Rochester

Views of a Clinical Study Report

To document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices.

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

NEUROENDOVASCULAR TRIALS

ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency

UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities

Human Research Protection Program. Investigator Manual

Introduction to Clinical Research

What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

Clinical Trial Basics:

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Hub Performance Assessment

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH SUPPORT OFFICE

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?

Human Subjects Protection Program Plan

St. Luke s University Health Network

Quality Control in Clinical Trials Blinding, Clinical Event Committees, Core Labs, and Data Standards

CHECKLIST: Pre-review

ClinicalTrials.gov Registration Guide

University of California, Irvine Human Research Protections Standard Operating Policies and Procedures

Investigational New Drug Development Steps for CRCs

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

BACKGROUND PURPOSE 9/24/2009 DATA AND SAFETY MONITORING

Source And Regulatory Documentation for DMID Clinical Studies

Advocate Health Care Network. Human Research Protection Program. Plan

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices

3.0 HSC Relation to Other KUMC Committees

4.1. Target Accrual Rate: The Target Accrual Goal divided by the Expected Duration (in days) of the trial.

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

SOP NUMBER: SC-404 Page 1 of 3

Transcription:

ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and the validity of data collected (White 2007). Federal Research Regulations and IRB Policy The Common Rule and FDA regulations state that the IRB may only approve research if there are adequate provisions for monitoring the data collected to ensure the safety of subjects (45 CFR 46.111(a)(6) & 21 CFR 812.4 & 312.5 6). NIH policy states that every clinical trial should have provisions for data and safety monitoring (NIH 1979). IRB Policy A data monitoring plan is required for all studies, no matter the risk level. The IRB requires that the full data monitoring plan be summarized in the IRB application. The study team must maintain the full data monitoring plan as part of the study operating procedures. Description A data monitoring plan must have provisions to monitor individual data points collected for data analysis, as well as required study documentation, such as IRB and sponsor documentation, consent documents, adverse event reports, etc. Elements of a data monitoring plan are discussed in detail below and include: Who is responsible for performing the data monitoring? How often will monitoring be performed? What components of the study will be monitored? How will monitoring be documented and responded to appropriately? Who is responsible for performing the data monitoring? One or more individuals may be responsible for monitoring all or specific aspects of the study data. These individuals may be internal to the study or may be independent of the study team. When writing this section of the plan, include: Justification that the number of individuals responsible for monitoring is enough to accomplish the monitoring activities. Justification that an independent monitor is or is not needed. o An independent monitor can view the data and documentation objectively, providing unbiased feedback to the study team. An independent monitor may also have Page 1 of 6

monitoring specific expertise, which allows the monitor to complete the review efficiently but thoroughly. The division of study components (see below) that are reviewed by each individual with monitoring responsibilities. o For example, the study coordinator reviews the consent and eligibility documentation, while the independent monitor reviews the case report forms and data set. How often will monitoring be performed? Monitoring should be conducted at an appropriate frequency to ensure that Additional risks to subjects can be identified in a timely manner such that decisions can be made about their care; Safety concerns about the study can be identified in a timely manner such that decisions can be made about the conduct of the study; Research documentation is complete; Data collection is complete, with as few missing data points as possible; Data is collected accurately, with no errors; Research data is valid, capturing all appropriate information that can be used to answer the research question. The frequency of monitoring may need to be increased for any of the following factors: The anticipated enrollment rate is high The number of data points being collected is large The eligibility criteria and the consent process is complex The study does not have a pre programmed data entry failsafe When writing this section of the plan, include justification that the intended frequency of monitoring satisfies all of the points described above. What components of the study will be monitored? In general, the following components can be monitored for all types of studies: Regulatory documentation This includes all documentation that must be maintained according to federal regulations, IRB policy, and institutional policy. o For example: all versions of the protocol, all IRB correspondence and approvals, all sponsor correspondence, all FDA correspondence, etc. Site operations Page 2 of 6

This includes all documentation of required qualifications and training of research staff, as well as documentation that study procedures were only performed by qualified personnel. Protocol compliance This includes documentation that all study procedures, from recruitment/enrollment through study closure, have been completed in compliance with the study protocol and study operating procedures. Subject research records This includes documentation all procedures for each participant have been performed and all required data points have been accurately recorded for each participant. Depending on the design and procedures in a study, there may be other components that require monitoring. The following list serves as an example of other components can also be monitored as applicable: Informed consent documentation This includes documentation that all participants have provided informed consent, using a consent process and a consent document approved by the IRB. Safety information This includes documentation that all adverse events and problems have been recorded in the study record and appropriately reported to the IRB, the sponsor, the FDA, etc. This also includes documentation that each event and problem has been considered by the PI and necessary oversight bodies to ensure that decisions are made to protect the safety of participants. Drug or device accountability This includes documentation that an investigation drug/device used in the study is appropriately accounted for at all times during the study. Tissue banking management and sample processing This includes documentation that all samples have been appropriately collected, processed, stored, and released according to the study protocol and consent document. Randomization procedures This includes documentation that all participants were randomized according to the procedures described in the approved protocol. Each component has a number of different items that must be confirmed in the study documentation. See Appendix A for a sample table that outlines some components and the types of items that can be confirmed. Page 3 of 6

Monitoring should be done in a systematic fashion, ensuring that all appropriate components are reviewed. The IRB has self assessment worksheets that outline various components and the items that can be confirmed during monitoring. However, there are components for which the IRB does not provide worksheets, because of the specific nature of study requirement. The study team is advised to create their own study specific monitoring worksheets in order to fulfill the needs to the study, based upon the study protocol and study operating procedures. How will monitoring be documented and responded to appropriately? After a monitoring review has been completed, a written report of the findings should be created. The PI should consider the findings with other members of the study team and determine if corrective actions are necessary, which may include: Amending the protocol or consent form Re consenting participants Additional data collection from participants Withdrawal of participants from the study Any changes made to IRB approved documents or information must be submitted to the IRB via an amendment application. The PI must also determine whether the findings and corrective actions must be reported to any of the following entities, as applicable: IRB Study sponsor Safety monitoring entity, such as a DSMB Regulatory agencies, such as the FDA Points to Address New Study Application: 1. Data Monitoring Plan page: Answer the questions by providing a summary of the overall data monitoring plan for the study. References & Links Article: Monitoring the Monitors White S, Field L, Wolf D. Monitoring the Monitors. Applied Clinical Trials. September 2007; p52 60 NIH Guidance NIH Guide for Grants and Contracts, Volume 8, No. 8 (1979) Page 4 of 6

Investigator Self Assessment Checklists Data and Safety Monitoring Plan Checklist Data and Safety Monitoring Guidance (IRB) http://www.research.utah.edu/irb/guidelines/selfassessment.html http://www.research.utah.edu/irb/guidelines/pdf/dsmp Checklist Sep09.pdf http://www.research.utah.edu/irb/guidelines/dsmb.html# Appendix A: Sample Table of Study Components, Items for Review, and Documentation This is an example only. This is not meant to be a comprehensive list of study components to review, nor does it reflect universal documentation to be reviewed for each component. Study component Items to be reviewed for this component Study documents to be reviewed for this component Monitoring review documentation Regulatory Documentation All versions of approved protocol in study file All versions of approved consent forms in study file Regulatory binder, protocol section Regulatory binder, consent section Regulatory Documentation Regulatory Documentation (etc.) (etc.) (etc.) Site Operations Documentation of PI involvement in conducting and supervising the study Responsibilities and tasks are delegated to qualified personnel See informed consent process checklist, eligibility criteria checklist, study meeting minutes, etc. See delegation log, IRB application, and study SOP Site Operations Site Operations (etc.) (etc.) (etc.) Protocol Compliance Inclusion/Exclusion criteria met per IRB approved protocol See approved protocol, eligibility criteria checklist, and individual participant source documentation Protocol Compliance Page 5 of 6

Screening, study procedures, etc. performed per IRB approved protocol See IRB approved protocol, CRFs titled Visit 1 and Visit 2, and individual participant source documentation Protocol Compliance (etc.) (etc.) (etc.) Additional rows can be added to this table to include all components that require monitoring. Page 6 of 6